Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly Profit After Tax of -$36.8 million in Q3 2025, down 16.24% quarter-over-quarter from -$31.6 million in Q2 2025, and down 46.04% on a YoY basis from -$68.1 million in Q3 2024.
Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$36.8 million for Q3 2025.
- In Q3 2025, Profit After Tax fell 46.04% year-over-year to -$36.8 million; the TTM figure through Sep 2025 stood at -$126.4 million (down 88.24% YoY), while the FY2024 annual figure was -$85.0 million, down 94.95% from the prior year.
- Profit After Tax was -$36.8 million for Q3 2025 at Dianthus Therapeutics, down from -$31.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$4.9 million in Q1 2022 to a low of -$36.8 million in Q3 2025.
- Historically, Profit After Tax has averaged -$17.2 million across 5 years, with a median of -$16.9 million in 2021.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax surged 72.09% in 2022, then plunged 168.39% in 2024.
- A 5-year view of Profit After Tax shows it stood at -$19.3 million in 2021, then jumped by 47.44% to -$10.1 million in 2022, then decreased by 4.62% to -$10.6 million in 2023, then slumped by 168.39% to -$28.5 million in 2024, then decreased by 29.13% to -$36.8 million in 2025.
- The last three Profit After Tax figures came in at -$36.8 million (Q3 2025), -$31.6 million (Q2 2025), and -$29.5 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -36.77 Mn |
| Jun 30, 2025 | -31.63 Mn |
| Mar 31, 2025 | -29.51 Mn |
| Dec 31, 2024 | -28.47 Mn |
| Sep 30, 2024 | -25.17 Mn |
| Jun 30, 2024 | -17.61 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -10.61 Mn |
| Sep 30, 2023 | -14.76 Mn |
| Jun 30, 2023 | -11.14 Mn |
| Mar 31, 2023 | -7.09 Mn |
| Dec 31, 2022 | -10.14 Mn |
| Sep 30, 2022 | -7.78 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Mar 31, 2022 | -4.88 Mn |
| Dec 31, 2021 | -19.29 Mn |
| Sep 30, 2021 | -17.43 Mn |
| Jun 30, 2021 | -16.93 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -18.17 Mn |